Search | OpenScholar

Search results

376 results found

Collaborations

Page

Natalya Shneyder, MD

Person: Sub-Investigator, Physician, Movement Disorder Specialist

Natalya Shneyder is an Assistant Professor of Neurology at University of South Florida Morsani College of Medicine in Tampa. She serves as a Movement Disorders Specialist at USF Health Byrd Parkinson’s Disease and Movement Disorders Center. Dr. Shneyder earned a medical degree from Zaporizhzhya...

Study Investigators. Dose Optimization of Apomorphine Sublingual Film for OFF Episodes in Parkinson's Disease: Is the Prophylactic Use of an Antiemetic Necessary? 2023 Mar 22. doi: 10.3233/JPD-223537. 2023;13(3):403-414. PMID: 36970914

Publication: Journal Article

Hauser, RA, WG Ondo, L Zhang, A Bowling, B Navia, E Pappert, and SH Isaacson. 2023. “Study Investigators. Dose Optimization of Apomorphine Sublingual Film for OFF Episodes in Parkinson’s Disease: Is the Prophylactic Use of an Antiemetic Necessary? 2023 Mar 22. Doi: 10.3233/JPD-223537. 2023;13(3):403-414. PMID: 36970914”. J Parkinsons Dis.

Abbreviated MDS-UPDRS for Remote Monitoring in PD Identified Using Exhaustive Computational Search. Parkinsons Dis. 2022 Jun 7;2022:2920255. doi: 10.1155/2022/2920255. eCollection 2022. PMID: 35711334

Publication: Journal Article

Morinan, G, RA Hauser, A Schrag, J Tang, J O’Keeffe, and MDS-NMS Scale Development Study Group. 2022. “Abbreviated MDS-UPDRS for Remote Monitoring in PD Identified Using Exhaustive Computational Search. Parkinsons Dis. 2022 Jun 7;2022:2920255. Doi: 10.1155/2022/2920255. ECollection 2022. PMID: 35711334”. Parkinsons Dis.

Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®). Parkinsonism Relat Disord 2021;82:133-137.

Publication: Journal Article

Hauser, RA, L Zeitlin, S Fisher, and R D’Souza. 2021. “Duration of Benefit Per Dose: Carbidopa-Levodopa Immediate Release Vs. Extended Release Capsules (Rytary®). Parkinsonism Relat Disord 2021;82:133-137.”. Parkonsonism Relat Disord.

Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study.

Publication: Journal Article

Patel, AT, MF Lew, K Dashtipour, S Isaacson, RA Hauser, W Ondo, P Maisonobe, S Wietek, B Rubin, and A Brashear. 2021. “Sustained Functional Benefits After a Single Set of Injections With AbobotulinumtoxinA Using a 2-ML Injection Volume in Adults With Cervical Dystonia: 12-Week Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3b Study.”. ECollection.

Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary®): Results of a Nationwide Dose Conversion Survey. Parkinsons Dis. 2021 Feb 19;2021:6638088. doi: 10.1155/2021/6638088. eCollection 2021.PMID: 33688424

Publication: Journal Article

Hauser, RA, G Banisadr, K Vuong, D Freilich, S Fisher, and R D’Souza. 2021. “Real-World Experience With Carbidopa-Levodopa Extended-Release Capsules (Rytary®): Results of a Nationwide Dose Conversion Survey. Parkinsons Dis. 2021 Feb 19;2021:6638088. Doi: 10.1155/2021/6638088. ECollection 2021.PMID: 33688424”. Parkonsons Dis.

A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's disease. Parkinsonism Relat Disord 2020;81:144-150.

Publication: Journal Article

Farbman, ES, CH Waters, PA LeWitt, M Rudinska, M Klingler, A Lee, J Qian, C Oh, and RA Hauser. 2020. “A 12-Month, Dose-Level Blinded Safety and Efficacy Study of Levodopa Inhalation Powder (CVT-301, Inbrija) in Patients With Parkinson’s Disease. Parkinsonism Relat Disord 2020;81:144-150.”. Parkinsonism Relat Disord.

Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice. CNS Spectr 2020;20:1-10.

Publication: Journal Article

Hauser, RA, JM Meyer, SA Factor, CL Comella, CM Tanner, RM Xavier, SN Caroff, and L Lundt. 2020. “Differentiating Tardive Dyskinesia: A Video-Based Review of Antipsychotic-Induced Movement Disorders in Clinical Practice. CNS Spectr 2020;20:1-10.”. CNS Spectr.

Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia. Clin Pharmacokinet 2019;58:77-88.

Publication: Journal Article

Hauser, RA, R Pahwa, WA Wargin, CJ Souza-Prien, N McClure, R Johnson, JT Nguyen, R Patni, and GT Went. 2018. “Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia. Clin Pharmacokinet 2019;58:77-88.”. Clin Pharmacokinet.